» Articles » PMID: 35441046

Artificial Scaffold Polypeptides As an Efficient Tool for the Targeted Delivery of Nanostructures In Vitro and In Vivo

Overview
Journal Acta Naturae
Specialty Biology
Date 2022 Apr 20
PMID 35441046
Authors
Affiliations
Soon will be listed here.
Abstract

The use of traditional tools for the targeted delivery of nanostructures, such as antibodies, transferrin, lectins, or aptamers, often leads to an entire range of undesirable effects. The large size of antibodies often does not allow one to reach the required number of molecules on the surface of nanostructures during modification, and the constant domains of heavy chains, due to their effector functions, can induce phagocytosis. In the recent two decades, targeted polypeptide scaffold molecules of a non-immunoglobulin nature, antibody mimetics, have emerged as much more effective targeting tools. They are small in size (3-20 kDa), possess high affinity (from subnano- to femtomolar binding constants), low immunogenicity, and exceptional thermodynamic stability. These molecules can be effectively produced in bacterial cells, and, using genetic engineering manipulations, it is possible to create multispecific fusion proteins for the targeting of nanoparticles to cells with a given molecular portrait, which makes scaffold polypeptides an optimal tool for theranostics.

Citing Articles

Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles.

Roberts S, Martin H, Al-Qallaf D, Tang A, Tiede C, Gaule T iScience. 2024; 27(8):110461.

PMID: 39104409 PMC: 11298639. DOI: 10.1016/j.isci.2024.110461.


Albumin incorporation into recognising layer of HER2-specific magnetic nanoparticles as a tool for optimal targeting of the acidic tumor microenvironment.

Kolesnikova O, Komedchikova E, Zvereva S, Obozina A, Dorozh O, Afanasev I Heliyon. 2024; 10(14):e34211.

PMID: 39100472 PMC: 11296017. DOI: 10.1016/j.heliyon.2024.e34211.


Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy.

Gabriele F, Palerma M, Ippoliti R, Angelucci F, Pitari G, Ardini M Int J Mol Sci. 2023; 24(10).

PMID: 37240041 PMC: 10218583. DOI: 10.3390/ijms24108680.


Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells.

Rosenkranz A, Slastnikova T Pharmaceutics. 2023; 15(3).

PMID: 36986848 PMC: 10055131. DOI: 10.3390/pharmaceutics15030987.


Targeted Two-Step Delivery of Oncotheranostic Nano-PLGA for HER2-Positive Tumor Imaging and Therapy In Vivo: Improved Effectiveness Compared to One-Step Strategy.

Shipunova V, Komedchikova E, Kotelnikova P, Nikitin M, Deyev S Pharmaceutics. 2023; 15(3).

PMID: 36986694 PMC: 10053351. DOI: 10.3390/pharmaceutics15030833.


References
1.
Peckys D, Korf U, de Jonge N . Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopy. Sci Adv. 2015; 1(6):e1500165. PMC: 4646781. DOI: 10.1126/sciadv.1500165. View

2.
Steemson J, Baake M, Rakonjac J, Arcus V, Liddament M . Tracking molecular recognition at the atomic level with a new protein scaffold based on the OB-fold. PLoS One. 2014; 9(1):e86050. PMC: 3896448. DOI: 10.1371/journal.pone.0086050. View

3.
Sandstrom M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D . Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. J Nucl Med. 2016; 57(6):867-71. DOI: 10.2967/jnumed.115.169342. View

4.
Tornoe C, Christensen C, Meldal M . Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem. 2002; 67(9):3057-64. DOI: 10.1021/jo011148j. View

5.
Grebenik E, Nadort A, Generalova A, Nechaev A, Sreenivasan V, Khaydukov E . Feasibility study of the optical imaging of a breast cancer lesion labeled with upconversion nanoparticle biocomplexes. J Biomed Opt. 2013; 18(7):76004. DOI: 10.1117/1.JBO.18.7.076004. View